Browsing Tag
MSD
11 posts
Kelun-Biotech reports strong Phase 3 data for sacituzumab tirumotecan in HR+/HER2- breast cancer
Kelun-Biotech’s sacituzumab tirumotecan doubled PFS in HR+/HER2- breast cancer. Find out what this means for patients, investors, and China’s ADC landscape.
Are AI-discovered vaccines the next big frontier in pharma?
AI-discovered vaccines are moving from hype to reality. See how Evaxion, BioNTech, DIOSynVax and Baseimmune are reshaping discovery—and why big pharma is buying.
Why Merck’s MSD is paying up to $600m for Evaxion’s undisclosed vaccine candidate EVX-B3
MSD licenses Evaxion’s AI-discovered vaccine EVX-B3 with $7.5M upfront and up to $592M in milestones—why this risky biotech bet could redefine vaccines.
Merck licenses innovative anti-cancer therapy LM-299 from LaNova Medicines
In a strategic move to broaden its oncology portfolio, Merck & Co., Inc. (NYSE: MRK), recognized globally as…
Sun Pharma introduces STARIZO to tackle drug-resistant skin infections in India
Sun Pharmaceutical Industries Limited has introduced STARIZO (Tedizolid Phosphate) to the Indian market, a novel antibacterial treatment targeting…
Aurobindo Pharma gets DCGI nod for Molnupiravir generic version
Aurobindo Pharma has secured consent from the Drugs Controller General of India (DCGI) for manufacturing and distributing its…
Gland Pharma gets FDA tentative approval for Sugammadex Injection
Gland Pharma has secured tentative approval from the US Food and Drug Administration (FDA) for Sugammadex Injection, 200…
Cipla, Dr. Reddy’s, and others to collaborate on Molnupiravir Covid trial
Five Indian pharma companies – Cipla, Dr. Reddy’s Laboratories, Emcure Pharmaceuticals, Sun Pharmaceutical Industries, and Torrent Pharmaceuticals will…
Divi’s Laboratories to manufacture API of MSD’s Covid drug Molnupiravir
Divi’s Laboratories Limited has been selected by pharma giant MSD (known as Merck in the US and Canada)…
Cipla partners with MSD to manufacture and distribute Molnupiravir drug to treat Covid-19
Cipla has entered into a non-exclusive licensing agreement with MSD (called Merck in the US and Canada) for…